UroGen Pharma Ltd. Ordinary Shares (URGN) Dividend History

UroGen Pharma Ltd. is a biotechnology company focused on developing innovative solutions for urological and uro-oncological conditions. The company's portfolio includes targeted therapies designed to improve treatment outcomes for patients with conditions such as bladder cancer and other genitourinary diseases. UroGen aims to leverage advanced drug delivery technologies to enhance safety and efficacy in urological treatments.

9 Ha'Ta'Asiya St, Ra'Anana, L3, 4365007
Phone: 972 9 770 7601
Website: https://www.urogen.com

Dividend History

UroGen Pharma Ltd. Ordinary Shares currently does not pay dividends

Company News

URGN Investors with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against UroGen Pharma Ltd.

Robbins LLP is investigating allegations that UroGen Pharma Ltd. failed to conduct a proper trial for its lead drug candidate UGN-102, leading to the FDA doubting the drug's effectiveness and the Oncological Drugs Advisory Committee voting against approving the drug's new drug application.

GlobeNewswire Inc.
UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA’s Briefing Document and Subsequent ODAC Vote Against UGN-102– Hagens Berman

UroGen Pharma Ltd. faces a securities class action lawsuit after the FDA's briefing document and ODAC's vote against its drug UGN-102, leading to a sharp drop in the company's stock price.

GlobeNewswire Inc.
Kirby McInerney LLP Reminds UroGen Pharma Ltd. (URGN) Investors of Class Action Filing and Encourages Investors to Contact the Firm

Kirby McInerney LLP has filed a class action lawsuit against UroGen Pharma Ltd. (URGN) on behalf of investors who purchased the company's securities from July 27, 2023, to May 15, 2025. The lawsuit alleges that the company failed to disclose issues with the design of the ENVISION clinical study for its drug UGN-102, which could impact the drug's approval.

GlobeNewswire Inc.
Iovance’s (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit– Hagens Berman

Iovance's cell therapy Amtagvi faced a slower-than-expected ramp-up, operational challenges, and higher-than-anticipated patient dropout rate, leading to a UBS downgrade and a securities class action lawsuit.

GlobeNewswire Inc.

Featured Companies: CODI IOVA
Deadline Alert: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

UroGen Pharma Ltd. (URGN) is facing a securities fraud lawsuit due to concerns about the design and efficacy of its drug UGN-102, which led to the FDA's rejection of its new drug application.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 04:27:31 UTC